Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.35
- Piotroski Score 5.00
- Grade Hold
- Symbol (CEMI)
- Company Chembio Diagnostics, Inc.
- Price $0.46
- Changes Percentage (0.22%)
- Change -$0
- Day Low $0.46
- Day High $0.46
- Year High $1.24
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/02/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.72
- Trailing P/E Ratio -0.63194444444444
- Forward P/E Ratio -0.63194444444444
- P/E Growth -0.63194444444444
- Net Income $-23,290,657
Income Statement
Quarterly
Annual
Latest News of CEMI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Henry Winkler Recalls Meeting 'Lovely' Queen Camilla -- and Reuniting with Steve Buscemi to Play a Pigeon (Exclusive)
Henry Winkler toured Ireland, Scotland, and England promoting his memoir. He had a memorable encounter with Queen Camilla at Ascot, and later recorded for DIRECTV in the UK with Steve Buscemi and Deio...
By PEOPLE.com | 1 month ago
